Cancer/Malignancies

CROI 2017: Stopping Smoking Cuts Risk of Some Cancers Quickly in People with HIV

Smoking probably contributes far more to the risk of cardiovascular disease in people with HIV than antiretroviral drug choice, viral load, or any factor linked to the virus, but stopping smoking leads to a rapid reduction in the risk of some cancers, according to results from a cluster of studies presented at the 2017 Conference on Retroviruses and Opportunistic Infections last week in Seattle.

alt

Read more:

CROI 2017: Treatment or Watchful Waiting for Cervical Abnormalities in Women with HIV?

Close monitoring of earlier-stage cervical abnormalities (CIN-2) may be preferable to treatment for many women with HIV, a U.S. study suggests. The findings, presented at the Conference on Retroviruses and Opportunistic Infections this week in Seattle, show that CIN-2 regressed in over three-quarters of women taking antiretroviral therapy, without the need for CIN treatment. A higher CD4 count was associated with a lower likelihood that lesions would progress.

alt

Read more:

CROI 2016: Study Does Not Support Routine HPV Vaccination to Prevent Anal Cancer in People with HIV

The quadrivalent HPV vaccine Gardasil does not protect older adults with HIV against persistent anal infection with human papillomavirus or the development of high-grade anal lesions (HSIL), but the ACTG A5298 study showed some evidence that it may protect against persistent oral HPV infection, Timothy Wilkin of Weill Cornell Medical College reported at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston.

alt

Read more:

IDWeek 2016: Only a Small Proportion of HIV+ Gay Men Receive Anal Cancer Screening

In the absence of national screening guidelines, only 11% of HIV-positive gay and bisexual men in the U.S. received anal Pap smears to detect anal cancer or precancerous cell changes during 2009-2012, with disparities between patient groups and variations across centers, according to a presentation at IDWeek, taking place this week in New Orleans.

alt

Read more:

CROI 2016: Early Antiretroviral Therapy Reduces the Risk of Infection-Related Cancers

People who started antiretroviral therapy at a CD4 cell count above 500 had a significantly lower risk of developing a cancer with an infectious cause when compared to people who started treatment at a CD4 count of 350 or below, an analysis of the START study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston has shown.

alt

Read more: